Novartis | NVS - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
AbbVie USD 3.58B 316M 2026-03
Amgen USD 1.58B 354M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Bausch Health Companies USD 813M 12M 2026-03
Biogen USD 554.3M 128.2M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Canopy Growth CAD 31.17M 2.27M 2026-03
Corcept Therapeutics USD 128.04M 13.3M 2026-03
Drreddys Laboratories INR 14.47B 12.45B 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Glaxosmithkline GBP 2.12B 1.44B 2026-03
J&J USD 6.42B 381M 2026-06
Merck USD 2.67B 180M 2026-03
Novartis USD 3.14B 296M 2026-03
Novartis USD 3.14B 296M 2026-03
Pacira USD 83.88M 7.99M 2026-03
Perrigo USD 267.3M 11.4M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Phibro Animal Health USD 78.32M 10.24M 2025-12
Prestige Brands USD 30.28M 606K 2026-03
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.33B 419M 2026-03
Sanofi EUR 2.49B 252M 2026-03
Supernus Pharmaceuticals USD 118.23M 4.16M 2026-03
Zoetis USD 588M 31M 2026-03